Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

A Randomized, Double-masked, Placebo-controlled, add-on Study to Assess the Efficacy of Oral Aliskiren 300 mg Once Daily for Diabetic Macular Edema

To assess the efficacy of oral aliskiren as a therapy for diabetic macular edema

Inclusion criteria:

• Type 1 or type 2 diabetes
• Diabetic macular edema

Exclusion criteria:

• Recent intra-ocular surgery in the study eye (e.g., cataract surgery in the last 6 months)
• Recent laser photocoagulation in the study eye
• Recent treatment with Avastin, Lucentis, or intravitreal corticosteroids in the study eye

Other protocol-defined inclusion/exclusion criteria applied